Latest Headlines

Latest Headlines

Biogen gives Roche 'renewed confidence' in its own failed Alzheimer's drugs

Biogen turned heads around the industry last month with early data in which its plaque-destroying Alzheimer's treatment had a significant effect on patients' cognition, bucking a vexing trend for such antibodies. Among those paying close attention was Roche, which is now re-examining a pair of once-failed treatments.

Pioneering study will test if trio of Roche, Lilly drugs can prevent Alzheimer's

Washington University School of Medicine in St. Louis has pieced together a pioneering new study that will help put a new theory on preventing Alzheimer's to a definitive test. And the outcome could help pave the way for a megablockbuster approach to treating a disease that afflicts millions.

Roche stakes its claim as the leader in high-risk Alzheimer's R&D

That dark cloud you've been watching form around the late-stage Alzheimer's drug development field has come equipped with a bright silver lining for Roche.

Big Pharma's high-risk pursuit of CNS gold faces major market doubts

Here's an interesting number for anyone interested in the risks and rewards of drug development: Two of every three analysts and fund managers recently queried by the ISI Group say they expect that new Alzheimer's drugs in late-stage testing at Eli Lilly and Pfizer/J&J will fail.

Roche spotlights PhI efficacy of Alzheimer's antibody

Roche has taken the first big clinical step in a long journey it hopes will lead to a mega-blockbuster market. The pharma giant says that a small, early-stage study of its experimental Alzheimer's